TheraRadar
Clinical-Stage Companies / Sovargen

Sovargen

Pre-Approval PRO BETA
2
Total Trials
0
Phase 3
1
Phase 2
0
Recruiting
19
Score

Pipeline by Phase

Phase 3
Phase 2
1
Phase 1
2

Therapeutic Focus

Focal Cortical Dysplasia Tuberous Sclerosis Complex (TSC) Hemimegalencephaly Pharmacokinetics

Clinical Trials (2)

NCT07287202 Phase 1 NOT YET RECRUITING

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Started: 3/1/2026

NCT05490095 Phase 1 COMPLETED

Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

Started: 7/23/2021

Drug Candidates

SVG103 SVG101 (T) Afinitor (R)
Activity Status: Active
Last Trial Started: 3/1/2026
Last Trial Ended: 2/7/2022
Trials (12 months): 1
Completed Trials: 1
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.